Re-Aim is a new early-stage pre-clinical company founded by Syncona, redefining how autoimmune diseases are treated by selectively depleting the pathogenic T cell subsets that drive chronic inflammation, autoimmunity and disease progression.

Founded: 2024
Founder: Asher Maroof PhD
Shareholding: 37.8%
Stage: Pre-clinical
Employees: 7
Seed financing: £7m

Unless stated all financials at 31 March 2026.

Re-Aim website

Re-Aim is a new early-stage pre-clinical company founded by Syncona during the year redefining how autoimmune diseases are treated by selectively depleting the pathogenic T cell subsets that drive chronic
inflammation, autoimmunity and disease progression.

Re-Aim aims to leverage its founder’s expertise alongside detailed analysis of patient samples to identify novel targets which define pathogenic subsets of Tcells in T-cell driven auto-immune diseases. The company plans to translate these findings over the coming year, nominating a development lead and moving towards an IND filing.

Syncona team

Roel Bulthuis

Roel Bulthuis is Managing Partner, Head of Investments of Syncona Investment Management Limited Roel is currently a Managing Partner at Syncona, where he manages the investment team and utilises more than 20 years of life science venture capital, business development and investment banking experience to help Syncona deliver value through the investment cycle. He is a Board member of iOnctura and A…

View Roel's biography

Position

Board member

Qualification

MSc, MBA